217 related articles for article (PubMed ID: 35512551)
1. Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia.
Mathur A; Ahn JB; Sutton W; Chu NM; Gross AL; Segev DL; McAdams-DeMarco M
Nephrol Dial Transplant; 2022 Oct; 37(11):2111-2118. PubMed ID: 35512551
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
3. Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes.
Mathur A; Sutton W; Ahn JB; Prescott JD; Zeiger MA; Segev DL; McAdams-DeMarco M
Transplantation; 2021 Dec; 105(12):e366-e374. PubMed ID: 33534525
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for secondary hyperparathyroidism.
Cozzolino M; Tomlinson J; Walsh L; Bellasi A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
[TBL] [Abstract][Full Text] [Related]
6. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
[TBL] [Abstract][Full Text] [Related]
7. Ultrasound in clinical setting of secondary hyperparathyroidism.
Meola M; Petrucci I; Cupisti A
J Nephrol; 2013; 26(5):848-55. PubMed ID: 23042437
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Salam SN; Khwaja A; Wilkie ME
Drugs; 2016 May; 76(8):841-52. PubMed ID: 27142279
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
10. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
Dudar I; Shifris I; Dudar S; Kulish V
Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
[TBL] [Abstract][Full Text] [Related]
11. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in pre-dialysis CKD patients.
Schumock GT; Andress D; E Marx S; Sterz R; Joyce AT; Kalantar-Zadeh K
Curr Med Res Opin; 2008 Nov; 24(11):3037-48. PubMed ID: 18826748
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
13. Decreasing Surgical Management of Secondary Hyperparathyroidism in the United States.
Fligor SC; Li C; Hamaguchi R; William J; James BC
J Surg Res; 2021 Aug; 264():444-453. PubMed ID: 33848844
[TBL] [Abstract][Full Text] [Related]
14. Prevention of secondary hyperparathyroidism in hemodialysis patients: the key role of native vitamin D supplementation.
Jean G; Vanel T; Terrat JC; Chazot C
Hemodial Int; 2010 Oct; 14(4):486-91. PubMed ID: 20955282
[TBL] [Abstract][Full Text] [Related]
15. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
16. Parathyroidectomy and survival in a cohort of Italian dialysis patients: results of a multicenter, observational, prospective study.
Tartaglione L; Rotondi S; Aucella F; Bonomini M; Caruso MR; Casino F; Cuzziol C; Farcomeni A; Filippini A; Lomonte C; Marinelli R; Rolla D; Rubino F; Seminara G; Pasquali M; Mazzaferro S;
J Nephrol; 2023 Sep; 36(7):1947-1955. PubMed ID: 37351832
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort.
Bozic M; Diaz-Tocados JM; Bermudez-Lopez M; Forné C; Martinez C; Fernandez E; Valdivielso JM
Nephrol Dial Transplant; 2022 Mar; 37(4):663-672. PubMed ID: 34021359
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
